Literature DB >> 16896161

Muscle glucose transport and phosphorylation in type 2 diabetic, obese nondiabetic, and genetically predisposed individuals.

Merri Pendergrass1, Alessandra Bertoldo, Riccardo Bonadonna, Gianluca Nucci, Lawrence Mandarino, Claudio Cobelli, Ralph A Defronzo.   

Abstract

Our objectives were to quantitate insulin-stimulated inward glucose transport and glucose phosphorylation in forearm muscle in lean and obese nondiabetic subjects, in lean and obese type 2 diabetic (T2DM) subjects, and in normal glucose-tolerant, insulin-resistant offspring of two T2DM parents. Subjects received a euglycemic insulin (40 mU.m(-2).min(-1)) clamp with brachial artery/deep forearm vein catheterization. After 120 min of hyperinsulinemia, a bolus of d-mannitol/3-O-methyl-d-[(14)C]glucose/d-[3-(3)H]glucose (triple-tracer technique) was given into brachial artery and deep vein samples obtained every 12-30 s for 15 min. Insulin-stimulated forearm glucose uptake (FGU) and whole body glucose metabolism (M) were reduced by 40-50% in obese nondiabetic, lean T2DM, and obese T2DM subjects (all P < 0.01); in offspring, the reduction in FGU and M was approximately 30% (P < 0.05). Inward glucose transport and glucose phosphorylation were decreased by approximately 40-50% (P < 0.01) in obese nondiabetic and T2DM groups and closely paralleled the decrease in FGU. The intracellular glucose concentration in the space accessible to glucose was significantly greater in obese nondiabetic, lean T2DM, obese T2DM, and offspring compared with lean controls. We conclude that 1) obese nondiabetic, lean T2DM, and offspring manifest moderate-to-severe muscle insulin resistance (FGU and M) and decreased insulin-stimulated glucose transport and glucose phosphorylation in forearm muscle; these defects in insulin action are not further reduced by the combination of obesity plus T2DM; and 2) the increase in intracelullar glucose concentration under hyperinsulinemic euglycemic conditions in obese and T2DM groups suggests that the defect in glucose phosphorylation exceeds the defect in glucose transport.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16896161     DOI: 10.1152/ajpendo.00617.2005

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  26 in total

1.  Handgrip strength is associated with insulin resistance and glucose metabolism in adolescents: Evidence from National Health and Nutrition Examination Survey 2011 to 2014.

Authors:  Shengxu Li; Rui Zhang; Guowei Pan; Liqiang Zheng; Changwei Li
Journal:  Pediatr Diabetes       Date:  2017-10-30       Impact factor: 4.866

2.  A new Michaelis-Menten-based kinetic model for transport and phosphorylation of glucose and its analogs in skeletal muscle.

Authors:  Hsuan-Ming Huang; Faramarz Ismail-Beigi; Raymond F Muzic
Journal:  Med Phys       Date:  2011-08       Impact factor: 4.071

3.  Sco2 deficient mice develop increased adiposity and insulin resistance.

Authors:  Shauna Hill; Sathyaseelan S Deepa; Kavithalakshmi Sataranatarajan; Pavithra Premkumar; Daniel Pulliam; Yuhong Liu; Vanessa Y Soto; Kathleen E Fischer; Holly Van Remmen
Journal:  Mol Cell Endocrinol       Date:  2017-04-18       Impact factor: 4.102

Review 4.  Insulin action and resistance in obesity and type 2 diabetes.

Authors:  Michael P Czech
Journal:  Nat Med       Date:  2017-07-11       Impact factor: 53.440

5.  Diabetes: Models, Signals, and Control.

Authors:  Claudio Cobelli; Chiara Dalla Man; Giovanni Sparacino; Lalo Magni; Giuseppe De Nicolao; Boris P Kovatchev
Journal:  IEEE Rev Biomed Eng       Date:  2009-01-01

6.  Uptake of 18F-labeled 6-fluoro-6-deoxy-D-glucose by skeletal muscle is responsive to insulin stimulation.

Authors:  Chandra Spring-Robinson; Visvanathan Chandramouli; William C Schumann; Peter F Faulhaber; Yanming Wang; Chunying Wu; Faramarz Ismail-Beigi; Raymond F Muzic
Journal:  J Nucl Med       Date:  2009-05-14       Impact factor: 10.057

Review 7.  Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009.

Authors:  R A DeFronzo
Journal:  Diabetologia       Date:  2010-04-02       Impact factor: 10.122

8.  Novel Agents for the Treatment of Type 2 Diabetes.

Authors:  Ralph A DeFronzo; Curtis L Triplitt; Muhammad Abdul-Ghani; Eugenio Cersosimo
Journal:  Diabetes Spectr       Date:  2014-05

Review 9.  Circadian Etiology of Type 2 Diabetes Mellitus.

Authors:  Naureen Javeed; Aleksey V Matveyenko
Journal:  Physiology (Bethesda)       Date:  2018-03-01

Review 10.  Skeletal muscle insulin resistance is the primary defect in type 2 diabetes.

Authors:  Ralph A DeFronzo; Devjit Tripathy
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.